Skip to content
Screener

Nektar Therapeutics NKTR Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$10.9MBeat by $169.6K
EPS-$1.82Miss by $0.08
Revenue estimate$10.7M
EPS estimate-$1.74

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$10.4M
EPS estimate-$2.13

Financials

Q1 2026

Income statement

See full
Revenue$10.9M+3.8%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.06B+1,531%
Enterprise value$2.14B+874%
P/S37.1×+35.7×

Profitability

See full
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Segments

By product

See full
Non Cash Royalty Revenue Related To Sale Of Future Royalties$10.9M+3.8%

FAQ

When did Nektar Therapeutics report Q1 2026 earnings?
Nektar Therapeutics (NKTR) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Nektar Therapeutics's Q1 2026 revenue and EPS?
Nektar Therapeutics reported revenue of $10.9M and eps of $-1.82 for Q1 2026.
Did Nektar Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $10.7M by $169.6K. EPS missed the consensus estimate of $-1.74 by $0.08.
How did Nektar Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.8% from $10.5M a year earlier and eps grew 44.8% from $-3.30.
Where can I find Nektar Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-053369) and the 10-Q periodic report (0001193125-26-212596) directly on SEC EDGAR. The filing index links above go to sec.gov.